TRIUMPH-5 Results: Retatrutide for Sleep Apnea

TRIUMPH-5 studies retatrutide for one of obesity's most disruptive complications: obstructive sleep apnea (OSA). An estimated 30 million Americans suffer from OSA, and the majority of cases are directly caused or worsened by excess weight. With retatrutide producing 24.2% average body weight loss in Phase 2 trials (Jastreboff et al., NEJM 2023), the potential to resolve sleep apnea for millions of patients is enormous. This trial could establish retatrutide as a medical alternative to lifelong CPAP dependence.

Understanding Obstructive Sleep Apnea

Obstructive sleep apnea occurs when the upper airway repeatedly collapses during sleep, causing breathing to stop for 10 seconds or more, often hundreds of times per night. Consequences include:

• Severe daytime fatigue: Fragmented sleep prevents restorative rest
• Cardiovascular risk: OSA doubles the risk of heart attack and stroke
• Cognitive impairment: Memory, concentration, and mood are significantly affected
• Quality of life: CPAP dependence, snoring, and fatigue affect relationships and daily function

Approximately 70% of OSA patients are obese. Excess weight deposits fat around the upper airway, tongue, and neck, narrowing the airway and making collapse more likely.

How Weight Loss Resolves Sleep Apnea

Weight loss reduces fat deposits in the tongue, soft palate, and lateral pharyngeal walls — the structures that collapse during apneic events. A 10% weight reduction typically reduces AHI by approximately 26%. At 24%, the reduction could approach 50-70%, potentially moving many patients from severe to mild or even normal AHI ranges.

TRIUMPH-5 Trial Design

• Population: Adults with obesity and moderate-to-severe OSA (AHI 15+)
• Estimated enrollment: ~500-800 participants
• Duration: 52-72 weeks
• Primary endpoint: Change in AHI from baseline
• Key secondary endpoints: Oxygen desaturation index, patient-reported sleepiness scores, CPAP usage, weight loss

Precedent: Tirzepatide for Sleep Apnea

Tirzepatide's SURMOUNT-OSA trial demonstrated significant AHI reductions in patients with obesity and OSA. About half of participants on tirzepatide achieved AHI below the diagnostic threshold for OSA. With retatrutide producing even greater weight loss, TRIUMPH-5 results could be even more striking.

Read more about retatrutide and sleep apnea.

What This Means for CPAP Users

• CPAP freedom: For patients who struggle with CPAP compliance, retatrutide could offer a pharmaceutical path to freedom from the machine
• Better sleep quality: Weight loss improves sleep quality beyond just reducing apneic events
• Cardiovascular protection: Resolving OSA reduces the doubled cardiovascular risk
• Energy and quality of life: Restored sleep quality improves daytime energy, mood, and cognitive function

Start Improving Sleep Today

Weight loss with current GLP-1 medications can already improve sleep apnea:

• Compounded semaglutide: $99/month
• Compounded tirzepatide: $125/month

Learn more about how to get started.